SK Chemicals Launches Korea’s First Migraine Treatment Complex ‘Subex’

[서울=뉴스핌] Reporter Kim Shin-young = A combination drug that can effectively treat migraines of various causes with two ingredients has been launched for the first time in Korea.

SK Chemicals announced on the 3rd that it has launched ‘Subex Tablets’ (Subex), a migraine treatment combination drug that contains two ingredients in one.

[서울=뉴스핌] Reporter Kim Shin-young = SK Chemicals Migraine Treatment Complex ‘Subex Tablets’ [사진=SK케미칼] 2024.09.03 sykim@newspim.com

Subex, launched by SK Chemicals, is a combination drug containing sumatriptan, a triptan-based drug commonly used to treat migraines, and naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID).

This is the first time that a two-ingredient combination drug has been launched in the domestic migraine treatment market, where single-ingredient treatments were previously prescribed.

Subex is a combination of two ingredients that can simultaneously treat migraines caused by different causes.

Migraine is a disease that causes throbbing pain like a heartbeat on one or both sides of the head due to dysfunction of the blood vessels and nerves around the brain. The main causes are known to be ▲cerebral blood vessel expansion due to secretion of neurotransmitters such as serotonin, dopamine, and calcitonin gene-related peptide (CGRP) ▲secretion of inflammatory substances in the meninges, etc.

The sumatriptan component of Subex relieves pain by reducing the neurotransmitter serotonin, and naproxen sodium suppresses neuroinflammation, making it an effective treatment for both causes.

Kim Yoon-ho, head of SK Chemicals’ Pharma business division, said, “Migraine is a disease that is directly related to the patient’s quality of life, as it not only causes pain from the disease itself, but also affects daily life and social life in general,” and added, “We will strive to develop and supply excellent migraine medications so that we can provide more diverse and convenient treatment options to patients suffering from migraines.”

Meanwhile, it has been approved as an acute treatment for migraine with or without aura in adult patients aged 18 years or older. The Korean Headache Society’s clinical guidelines recommend combined therapy with triptan drugs and naproxen sodium as a treatment drug for rapid pain relief.

sykim@newspim.com